SP-0116: Extension of dose-volume metrics using imaging  by Partridge, M.
S44  2nd ESTRO Forum 2013	
traditionally done by physicians or physicists and play an important 
role in the multidisciplinary implementation of new treatment 
techniques. There are now significant opportunities for RTTs to 
develop their role within the radiotherapy team, promote excellence 
in patient care and engage in research. 
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Relationships between dose delivered to an organ at risk and 
radiation-induced complications have been studied for many years. 
Complications are often either dichotomised (present or not present) 
or coarsely graded using a 4-point scale. The three-dimensional dose 
distribution over a particular organ is also typically summarized using 
a simple mean dose, or as a dose-volume or dose-surface histogram 
(DVH or DSH). Thresholds, such as the volume receiving more than 
given dose (Vd) can be extracted from the histogram, or the 
histograms can be reduced further to a single number expressing 
normal tissue complication probability (NTCP).  
DVH reduction models have shown some success in predicting clinical 
outcomes, but all spatial dosimetric information is lost. For hollow 
organs, such as the rectum, models explicitly including the shape of 
dose distribution have been shown to provide stronger correlations 
with outcome than simple DSHs. Furthermore, different toxic end 
points have been shown to be associated with different features the 
dose distribution: rectal bleeding with lateral extent of the dose 
distribution and loose stools with longitudinal extent, whilst proctitis 
was associated most strongly with the DSHs itself. This indicates that, 
in addition to improving predictive power, the inclusion of spatial 
information in the NTCP model also has the potential to give insight 
into the mechanism behind various toxicities. The 2-dimensional DSH-
based models can also be extended consider the 3-dimensional dose 
distribution: dose tolateral and cranial component of parotid gland 
during head and neck radiotherapy has been shown to increase the 
risk of xerostomia. Interestingly, non-dosimetric factors were also 
included in this modelling and submandibular gland removal was 
shown to be an independent risk factor for xerostomia. 
The clinical severity of radiation-induced toxicity to a large “parallel” 
organ may depend on the baseline functional reserve. Lung perfusion 
SPECT or hyperpolarized gas ventilation MRI have been shown to be 
capable of mapping baseline lung function in lung cancer patients. 
Predictors of toxicity such as perfusion-weighted mean lung dose or 
perfusion-weighted DVHs can then be used to more accurately 
estimate the effects of treatment. These “functional DVHs” have been 
demonstrated to be useful for creating radiotherapy plans which 
preferentially avoid healthy, well-perfused lung. Similar approaches 
are also possible in the treatment of liver cancer, where it has been 
shown that maps of baseline function can be produced using dynamic 
contrast-enhanced CT, HIDA, GSA or mebrofenin SPECT and FDGal 
PET. 
In summary, the predictive power of traditional DVH reduction 
methods which summarize the 3D dose distribution in an organ at risk 
with a single number has been shown to be improved by adding 
additional information. Spatial dosimetric information has been shown 
to not only give stronger associations with treatment outcome, but 
also give insight into the mechanism behind various toxicities. 
Functional imaging can help assess functional reserve in parallel 
organs, allowing selective avoidance of healthy portions of damaged 
organs such as the liver and lungs and hybrid models incorporating 
dosimetric and non-dosimetric information have shown promise. To be 
useful in routine clinical practise implementation within commercial 
treatment planning systems and dose optimisation engines is required, 
together with more extensive validation against clinical outcome 
data. 
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The ability to predict individual risk of radiation-induced normal tissue 
complications is a long sought goal in radiobiology. During the last 
decade, substantial efforts have been made to establish a gene based 
predictive test for normal tissue radiosensitivity. Around 80 candidate 
gene studies have explored possible associations between SNPs and 
the risk of normal tissue complications after radiotherapy. Although 
around two-thirds of the studies reported significant associations, the 
results have been very inconsistent and independent confirmation of 
the associations rarely took place. In hindsight, it seems obvious that 
many of the studies published so far have suffered from severe 
methodological shortcomings of which insufficient statistical power 
and lack of correction for multiple testing are among the most 
prominent (1). 
After quite a teething period, substantial progress is currently being 
made in radiogenomic research. A number of important lessons have 
been learned from other research fields (2). There is a growing 
consensus that studies addressing SNPs need to be powered to detect 
rather small differences in toxicity risk. Two of the largest SNP studies 
ever conducted in normal tissue radiobiology, including more than 
1,600 and 2,000 patients, have recently been published (3,4) of which 
one actually reports a compelling association for a SNP near the TNF-
alpha gene. Cooperative research groups are increasingly active in the 
field. A large international meta-analysis addressing a TGF-beta1 SNP, 
comprising individual patient level data on 2,782 patients from 11 
cohorts, has been published (5). The first genome-wide association 
study in normal tissue radiobiology has been conducted and more are 
underway. These developments are certainly warranted and heraldt 
hat interesting discoveries will be made in the years to come. 
Nevertheless, the human genome has some fundamental 
characteristics that are challenging to deal with from a statistical 
point of view. Furthermore a number of clinical and dosimetrical 
issues need to be taken carefully into consideration in radiogenomic 
research (6). 
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Radiobiology and physics are closely coupled in considering the 
benefits versus the concerns of delivering brachytherapy, particularly 
as a boost in an already irradiated volume. Clearly, it is essential that 
the target volume is easily accessible to placement of intracavity 
applicators, catheters or seeds particularly if the brachytherapy is 
fractionated. Therefore brachytherapy tends to be most adopted as an 
alternative or additional modality to external beam delivery in the 
treatment of cancers in cervix, anus, rectum, head and neck, 
prostate, breast and skin. 
Since the source of radiation dose in brachytherapy is within the 
target volume, the dose fall-off outside the target volume is much 
more rapid compared with external beam treatment plans. For 
example comparing irradiation of prostate using high dose-rate 
brachytherapy with external beam plans, dose fall-off is 4–5 times 
greater with distance away from the organ in the brachytherapy. This 
more rapid dose fall-off outside the target volume also gives a major 
